References
- Obergrussberger A, Goetze TA, Brinkwirth N, et al. An update on the advancing high-throughput screening techniques for patch clamp-based ion channel screens: implications for drug discovery. Expert Opin Drug Discov. 2018;13(3):269–277. doi: 10.1080/17460441.2018.1428555
- Bell DC, Dallas ML. Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia. Br J Pharmacol. 2018;175(12):2312–2321. doi: 10.1111/bph.13916
- Rapedius M, Obergrussberger A, Humphries ESA, et al. There is no F in APC: using physiological fluoride-free solutions for high throughput automated patch clamp experiments. Front Mol Neurosci. 2022;15:982316. doi: 10.3389/fnmol.2022.982316
- Obergrussberger A, Friis S, Brüggemann A, et al. Automated patch clamp in drug discovery: major breakthroughs and innovation in the last decade. Expert Opin Drug Discov. 2021;16(1):1–5. doi: 10.1080/17460441.2020.1791079
- Obergrussberger A, Stölzle-Feix S, Becker N, et al. Novel screening techniques for ion channel targeting drugs. Channels. 2015;9(6):367–375. doi: 10.1080/19336950.2015.1079675
- Dunlop J, Bowlby M, Peri R, et al. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat Rev Drug Discov. 2008;7(4):358–368. doi: 10.1038/nrd2552
- Kang SK, Vanoye CG, Misra SN, et al. Spectrum of KV2.1 dysfunction in KCNB1-associated neurodevelopmental disorders. Ann Neurol. 2019;86(6):899–912. doi: 10.1002/ana.25607
- Calhoun JD, Vanoye CG, Kok F, et al. Characterization of a KCNB1 variant associated with autism, intellectual disability, and epilepsy. Neurol Genet. 2017;3(6):e198. doi: 10.1212/NXG.0000000000000198
- Thompson CH, Potet F, Abramova TV, et al. Epilepsy-associated SCN2A (NaV1.2) variants exhibit diverse and complex functional properties. J Gen Physiol. 2023;155:e202313375. doi: 10.1085/jgp.202313375
- Ng CA, Perry MD, Liang W, et al. High-throughput phenotyping of heteromeric human ether-à-go-go-related gene potassium channel variants can discriminate pathogenic from rare benign variants. Hear Rhythm. 2020;17(3):492–500. doi: 10.1016/j.hrthm.2019.09.020
- Gertler TS, Thompson CH, Vanoye CG, et al. Functional consequences of a KCNT1 variant associated with status dystonicus and early-onset infantile encephalopathy. Ann Clin Transl Neurol. 2019;6(9):1606–1615. doi: 10.1002/acn3.50847
- Vanoye CG, Desai RR, Fabre KL, et al. High-throughput functional evaluation of KCNQ1 decrypts variants of unknown significance. Circ Genomic Precis Med. 2018;11(11):e002345. doi: 10.1161/CIRCGEN.118.002345
- Glazer AM, Wada Y, Li B, et al. High-throughput reclassification of SCN5A variants. Am J Hum Genet. 2020;107(1):111–123. doi: 10.1016/j.ajhg.2020.05.015
- Calloe K, Broendberg AK, Christensen AH, et al. Multifocal atrial and ventricular premature contractions with an increased risk of dilated cardiomyopathy caused by a NaV1.5 gain-of-function mutation (G213D). Int J Cardiol. 2018;257:160–167. doi: 10.1016/j.ijcard.2017.11.095
- Heyne HO, Baez-Nieto D, Iqbal S, et al. Predicting functional effects of missense variants in voltage-gated sodium and calcium channels. Sci Transl Med. 2020;12(556):eaay6848. doi: 10.1126/scitranslmed.aay6848
- Pan JQ, Baez-Nieto D, Allen A, et al. Developing high-throughput assays to analyze and screen electrophysiological phenotypes. Methods Mol Biol. 2018;1787:235–252.
- Baez-Nieto D, Allen A, Akers-Campbell S, et al. Analysing an allelic series of rare missense variants of CACNA1I in a Swedish schizophrenia cohort. Brain. 2022;145(5):1839–1853. doi: 10.1093/brain/awab443
- ICH topic S 7 B the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals [Internet]. 2005 [cited 2024 Jan 23]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-7-b-nonclinical-evaluation-potential-delayed-ventricular-repolarization-qt-interval_en.pdf
- Sager PT, Gintant G, Turner JR, et al. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the cardiac safety research consortium. Am Heart J. 2014;167(3):292–300. doi: 10.1016/j.ahj.2013.11.004
- Gintant G, Sager PT, Stockbridge N. Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov. 2016;15(7):457–471. doi: 10.1038/nrd.2015.34
- Fermini B, Hancox JC, Abi-Gerges N, et al. A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. J Biomol Screen. 2016;21(1):1–11. doi: 10.1177/1087057115594589
- Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017;16(1):19–34. doi: 10.1038/nrd.2016.230
- Sriram K, Insel PA. G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol Pharmacol. 2018;93(4):251–258. doi: 10.1124/mol.117.111062
- Yekkirala AS, Roberson DP, Bean BP, et al. Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov. 2017;16(8):545–564. doi: 10.1038/nrd.2017.87
- Mulcahy JV, Pajouhesh H, Beckley JT, et al. Challenges and opportunities for therapeutics targeting the voltage-gated sodium channel isoform NaV1.7. Physiol Behav. 2017;176:139–148. doi: 10.1016/j.physbeh.2017.03.040
- Eagles DA, Chow CY, King GF. Fifteen years of NaV1.7 channels as an analgesic target: why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy? Br J Pharmacol. 2022;179(14):3592–3611. doi: 10.1111/bph.15327
- Deng L, Dourado M, Reese RM, et al. NaV1.7 is essential for nociceptor action potentials in the mouse in a manner independent of endogenous opioids. Neuron. 2023;111(17):2642–2659.e13. doi: 10.1016/j.neuron.2023.05.024
- Bagal SK, Kemp MI, Bungay PJ, et al. Discovery and optimisation of potent and highly subtype selective NaV1.8 inhibitors with reduced cardiovascular liabilities. Med Chem Commun. 2016;7(10):1925–1931. doi: 10.1039/C6MD00281A
- Jones J, Correll DJ, Lechner SM, et al. Selective inhibition of NaV1.8 with VX-548 for acute pain. N Engl J Med. 2023;389(5):393–405. doi: 10.1056/NEJMoa2209870
- Praxis Precision Medicines announces positive topline results from PRAX-628 phase 1 study enabling best-in-class profile [Internet]. 2023 [cited 2024 Jan 22]. Available from: https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results
- AlphaNavi Pharma Inc., announces initiation of a phase 1/2 clinical trial of ANP-230 in patients with familial infantile episodic limb pain [Internet]. 2021 [cited 2024 Jan 22]. Available from: https://alphanavi.com/en/2021/05/11/236/
- Biohaven presents expanded EEG and safety data for BHV-7000 at the American epilepsy society annual meeting [Internet]. 2023 [cited 2024 Jan 22]. Available from: https://www.prnewswire.com/news-releases/biohaven-presents-expanded-eeg-and-safety-data-for-bhv-7000-at-the-american-epilepsy-society-annual-meeting-302002684.html
- Wainger BJ, Macklin EA, Vucic S, et al. Effect of Ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78(2):186–196. doi: 10.1001/jamaneurol.2020.4300
- QurAlis. QurAlis announces first-in-human dose in phase 1 clinical trial of QRL-101, a First-in-class Kv7 precision therapy for ALS [Internet]. 2023 [cited 2024 Jan 22]. Available from: https://www.prnewswire.com/news-releases/quralis-announces-first-in-human-dose-in-phase-1-clinical-trial-of-qrl-101-a-first-in-class-kv7-precision-therapy-for-als-301712631.html
- Hearing loss company acousia therapeutics completes clinical phase 1 study with its small molecule [Internet]. 2022 [cited 2024 Jan 22]. Available from: https://www.acousia.com/hearing-loss-company-acousia-therapeutics-completes-clinical-phase-1-study-with-its-small-molecule/
- Acousia given go ahead for hearing loss phase II trial [Internet]. 2023 [cited 2024 Jan 22]. Available from: https://www.clinicaltrialsarena.com/news/acousia-given-go-ahead-for-hearing-loss-phase-ii-trial/
- FDA OKs bridge biotherapeutics’ clinical trial of IPF drug candidate [Internet]. 2023 [cited 2024 Jan 23]. Available from: https://www.koreabiomed.com/news/articleView.html?idxno=22726
- DES-7114 by Eli Lilly and Co for ulcerative colitis: likelihood of approval [Internet]. 2024 [cited 2024 Jan 23]. Available from: https://www.pharmaceutical-technology.com/data-insights/des-7114-eli-lilly-and-co-ulcerative-colitis-likelihood-of-approval/
- D.E. Shaw Research Licenses first-in-class therapeutic for immunological diseases to Lilly [internet]. 2022 [cited 2024 Jan 23]. Available from: https://www.prnewswire.com/news-releases/d-e-shaw-research-licenses-first-in-class-therapeutic-for-immunological-diseases-to-lilly-301566618.html
- Cerevance doses first subject in phase 1 clinical study of CVN293, a selective Inhibitor of KCNK13 designed to selectively modulate neuroinflammation, for the treatment of ALS and alzheimer’s disease [Internet]. 2023 [cited 2024 Jan 23]. Available from: https://www.cerevance.com/media/cerevance-doses-first-subject-in-phase-1-clinical-study-of-cvn293-a-selective-inhibitor-of-kcnk13-designed-to-selectively-modulate-neuroinflammation-for-the-treatment-of-als-and-alzheimers-disease
- Chan P, Ding HT, Liederer BM, et al. Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor. Clin Transl Sci. 2021;14(5):1945–1954. doi: 10.1111/cts.13049
- First volunteer dosed in phase 1 trial of SION-638 [Internet]. 2022 [cited 2024 Jan 23]. Available from: https://cysticfibrosisnewstoday.com/news/first-participant-dosed-cf-therapy-sion-638-phase-1-trial/
- Russell P, Woodward K, Charlwood J, et al. ETD001: a long-acting inhaled ENaC blocker, is well tolerated in humans. Eur Respir J. 2022;60:4338.
- Enterprise Therapeutics - Pipeline [Internet]. 2023 [cited 2024 Jan 23]. Available from: https://enterprisetherapeutics.com/pipeline/
- NMD Pharma reports positive top-line data from a phase I/IIa clinical trial of NMD670 in patients with myasthenia gravis [Internet]. 2022 [cited 2024 Jan 23]. Available from: https://www.nmdpharma.com/news/nmd670-top-line-data
- NMD Pharma initiates phase I safety, tolerability and pharmacokinetics study of NMD1343 [Internet]. 2023 [cited 2024 Jan 23]. Available from: https://www.nmdpharma.com/news/nmd1343news
- AK-1780 by Eli Lilly and Co for pain: likelihood of approval [Internet]. 2024 [cited 2024 Jan 23]. Available from: https://www.pharmaceutical-technology.com/data-insights/ak-1780-eli-lilly-and-co-pain-likelihood-of-approval/?cf-view
- Eliem provides update on ETX-810 and ETX-155 clinical programs [Internet]. 2022 [cited 2024 Jan 23]. Available from: https://ir.eliemtx.com/news-releases/news-release-details/eliem-provides-update-etx-810-and-etx-155-clinical-programs
- Engrail Therapeutics announces positive results of ENX-101 phase 1b clinical study and prepares for initiation of ENACT phase 2 trial in focal epilepsy [Internet]. 2022 [cited 2024 Jan 23]. Available from: https://www.engrail.com/engrail-therapeutics-announces-positive-results-of-enx-101-phase-1b-clinical-study-and-prepares-for-initiation-of-enact-phase-2-trial-in-focal-epilepsy/
- Goeldner C, Kishnani PS, Skotko BG, et al. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with down syndrome. J Neurodev Disord. 2022;14(1):10. doi: 10.1186/s11689-022-09418-0
- Gilgamesh Pharmaceuticals successfully completes phase 1 SAD/MAD clinical trials of GM-1020 [Internet]. 2023 [cited 2024 Jan 23]. Available from: https://www.prnewswire.com/news-releases/gilgamesh-pharmaceuticals-successfully-completes-phase-1-sadmad-clinical-trials-of-gm-1020-301934271.html
- FDA approves rapid-acting auvelity for major depression [Internet]. 2022 [cited 2024 Jan 23]. Available from: https://www.formularywatch.com/view/fda-approves-rapid-acting-auvelity-for-major-depression
- Alto Neuroscience - programs [internet]. 2023 [cited 2024 Jan 23]. Available from: https://www.altoneuroscience.com/programs
- Kineta announces first participant dosed in phase 1 multiple ascending dose clinical trial of KCP506 [Internet]. 2021 [cited 2024 Jan 23]. Available from: https://kinetabio.com/2021/07/14/kineta-announces-first-participant-dosed-in-phase-1-multiple-ascending-dose-clinical-trial-of-kcp506/
- Eliem therapeutics provides strategic update and announces leadership transition media [Internet]. 2023. Available from: https://ir.eliemtx.com/news-releases/news-release-details/eliem-therapeutics-provides-strategic-update-and-announces
- Biohaven. Biohaven announces positive data from its exploratory electroencephalogram (EEG) biomarker study of BHV-7000, completion of once-daily formulation development, and plan to initiate phase 3 pivotal studies [Internet]. [cited 2024 Jan 22]. Available from: https://www.prnewswire.com/news-releases/biohaven-announces-positive-data-from-its-exploratory-electroencephalogram-eeg-biomarker-study-of-bhv-7000-completion-of-once-daily-formulation-development-and-plan-to-initiate-phase-3-pivotal-studies-301917174.htm
- French JA, Porter RJ, Perucca E, et al. Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal epilepsy: a phase 2b randomized clinical trial. JAMA Neurol. 2023;80(11):1145–1154. doi: 10.1001/jamaneurol.2023.3542
- Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7(1):1–11. doi: 10.1016/j.celrep.2014.03.019
- McNeish J, Gardner JP, Wainger BJ, et al. From dish to bedside: lessons learned while translating findings from a stem cell model of disease to a clinical trial. Cell Stem Cell. 2015;17(1):8–10. doi: 10.1016/j.stem.2015.06.013
- Huang X, Roet KCD, Zhang L, et al. Human amyotrophic lateral sclerosis excitability phenotype screen: target discovery and validation. Cell Rep. 2021;35(10):109224. doi: 10.1016/j.celrep.2021.109224
- Zhao Y, Huang G, Wu J, et al. Molecular basis for ligand modulation of a mammalian voltage-gated Ca2+ channel. Cell. 2019;177(6):1495–1506.e12. doi: 10.1016/j.cell.2019.04.043
- Yao X, Gao S, Yan N. Structural basis for pore blockade of human voltage-gated calcium channel CaV1.3 by motion sickness drug cinnarizine. Cell Res. 2022;32(10):946–948. doi: 10.1038/s41422-022-00663-5
- Dong Y, Gao Y, Xu S, et al. Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2.2. Cell Rep. 2021;37(5):109931. doi: 10.1016/j.celrep.2021.109931
- Zhao Y, Huang G, Wu Q, et al. Cryo-EM structures of apo and antagonist-bound human CaV3.1. Nature. 2019;576(7787):492–497. doi: 10.1038/s41586-019-1801-3
- He L, Yu Z, Geng Z, et al. Structure, gating, and pharmacology of human CaV3.3 channel. Nat Commun. 2022;13(1):2084. doi: 10.1038/s41467-022-29728-0
- Nguyen PT, Yarov-Yarovoy V. Towards structure-guided development of pain therapeutics targeting voltage-gated sodium channels. Front Pharmacol. 2022;13:842032. doi: 10.3389/fphar.2022.842032
- Masiulis S, Desai R, Uchański T, et al. GABAA receptor signalling mechanisms revealed by structural pharmacology. Nature. 2019;565(7740):454–459. doi: 10.1038/s41586-018-0832-5
- Zhu S, Sridhar A, Teng J, et al. Structural and dynamic mechanisms of GABAA receptor modulators with opposing activities. Nat Commun. 2022;13(1):4582. doi: 10.1038/s41467-022-32212-4
- Hansen KB, Yi F, Perszyk RE, et al. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018;150(8):1081–1105. doi: 10.1085/jgp.201812032
- Wisedchaisri G, Gamal El-Din TM. Druggability of voltage-gated sodium channels—exploring old and new drug receptor sites. Front Pharmacol. 2022;13:858348. doi: 10.3389/fphar.2022.858348
- Wu Q, Huang J, Fan X, et al. Structural mapping of NaV1.7 antagonists. Nat Commun. 2023;14(1):3224. doi: 10.1038/s41467-023-38942-3
- Huang J, Fan X, Jin X, et al. Cannabidiol inhibits NaV channels through two distinct binding sites. Nat Commun. 2023;14(1):3613. doi: 10.1038/s41467-023-39307-6
- Kschonsak M, Jao CC, Arthur CP, et al. Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors. Elife. 2023;12:e84151. doi: 10.7554/eLife.84151
- Li T, Lu G, Chiang EY, et al. High-throughput electrophysiological assays for voltage gated ion channels using SyncroPatch 768PE. PLoS One. 2017;12(7):e0180154. doi: 10.1371/journal.pone.0180154
- Chambers C, Witton I, Adams C, et al. High-throughput screening of NaV1.7 modulators using a giga-seal automated patch clamp instrument. Assay Drug Dev Technol. 2016;14(2):93–108. doi: 10.1089/adt.2016.700
- Wolkenberg SE, Zhao Z, Mulhearn JJ, et al. High concentration electrophysiology-based fragment screen: discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors. Bioorg Med Chem Lett. 2011;21(9):2646–2649. doi: 10.1016/j.bmcl.2010.12.115
- Ridley J, Manyweathers S, Tang R, et al. Development of ASIC1a ligand-gated ion channel drug screening assays across multiple automated patch clamp platforms. Front Mol Neurosci. 2022;15:982689. doi: 10.3389/fnmol.2022.982689
- Obergrussberger A, Rinke-Weiß I, Goetze TA, et al. The suitability of high throughput automated patch clamp for physiological applications. J Physiol. 2022;600(2):277–297. doi: 10.1113/JP282107
- Braun N, Friis S, Ihling C, et al. High-throughput characterization of 309 photocrosslinker-bearing ASIC1a variants maps residues critical for channel function and pharmacology. PLoS Biol. 2021;19:e3001321. doi: 10.1371/journal.pbio.3001321
- Milligan CJ, Jiang LH Automated planar patch-clamp recording of P2X receptors. Methods mol biol. 2020; p. 285–300.
- Obergrussberger A, Haarmann C, Rinke I, et al. Automated patch clamp analysis of nAchα7 and NaV1.7 channels. Curr Protoc Pharmacol. 2014;65(1):11.13.1–11.13.48. doi: 10.1002/0471141755.ph1113s65
- Seibertz F, Rapedius M, Fakuade FE, et al. A modern automated patch-clamp approach for high throughput electrophysiology recordings in native cardiomyocytes. Commun Biol. 2022;5(1):969. doi: 10.1038/s42003-022-03871-2
- Seibertz F, Sutanto H, Dülk R, et al. Electrophysiological and calcium ‑ handling development during long ‑ term culture of human ‑ induced pluripotent stem cell ‑ derived cardiomyocytes. Basic Res Cardiol. 2023;118:14. doi: 10.1007/s00395-022-00973-0
- McKeithan WL, Feyen DAM, Bruyneel AAN, et al. Reengineering an antiarrhythmic drug using patient hiPSC cardiomyocytes to improve therapeutic potential and reduce toxicity. Cell Stem Cell. 2020;27(5):813–821.e6. doi: 10.1016/j.stem.2020.08.003
- Haythornthwaite A, Stoelzle S, Hasler A, et al. Characterizing Human Ion Channels in Induced Pluripotent Stem Cell–Derived Neurons. J Biomol Screen. 2012;17:1264–1272. doi: 10.1177/1087057112457821
- Becker N, Stoelzle S, Göpel S, et al. Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system. J Pharmacol Toxicol Methods. 2013;68(1):82–87. doi: 10.1016/j.vascn.2013.03.009
- Yuan NY, Poe MM, Witzigmann C, et al. Characterization of GABAA receptor ligands with automated patch-clamp using human neurons derived from pluripotent stem cells. J Pharmacol Toxicol Methods. 2016;82:109–114. doi: 10.1016/j.vascn.2016.08.006
- Franz D, Olsen HL, Klink O, et al. Data Descriptor : Automated and manual patch clamp data of human induced pluripotent stem cell-derived dopaminergic neurons. Sci Data. 2017;4(1):170056. doi: 10.1038/sdata.2017.56
- Toh MF, Brooks JM, Strassmaier T, et al. Application of high-throughput automated patch-clamp electrophysiology to study voltage-gated ion channel function in primary cortical cultures. SLAS Discov. 2020;25(5):447–457. doi: 10.1177/2472555220902388
- Ghovanloo MR, Tyagi S, Zhao P, et al. High-throughput combined voltage-clamp/current-clamp analysis of freshly isolated neurons. Cell Reports Methods. 2023;3(1):100385. doi: 10.1016/j.crmeth.2022.100385
- Truong V, Randolph A, Lu I, et al. Transcriptome profiling of multiple human induced pluripotent stem cell derived sensory neuron populations and functional validation of pain targets on automated patch clamp systems. neurosci meet plan 2023:PSTR250.08.
- Tavares-Ferreira D, Shiers S, Ray PR, et al. Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors. Sci Transl Med. 2022;14(632):eabj8186. doi: 10.1126/scitranslmed.abj8186
- Nalls MA, P N, CM L, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet. 2014;46:989–993.10.1038/ng.3043 9
- Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-genome wide association study. Lancet Neurol. 2019;18:1091–1102. 12 10.1016/S1474-4422(19)30320-5
- Jinn S, Drolet RE, Cramer PE, et al. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α -synuclein aggregation. Proc Natl Acad Sci. 2017;114(9):2389–2394. doi: 10.1073/pnas.1616332114
- Chen C-C, Keller M, Hess M, et al. A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV. Nat Commun. 2014;5(1):4681. doi: 10.1038/ncomms5681
- Bazzone A, Barthmes M, George C, et al. A comparative study on the lysosomal cation channel TMEM175 using automated whole-cell patch-clamp, lysosomal patch-clamp, and solid supported membrane-based electrophysiology: functional characterization and high-throughput screening assay development. Int J Mol Sci. 2023;24(16):12788. doi: 10.3390/ijms241612788
- Schieder M, Rötzer K, Brüggemann A, et al. Planar patch clamp approach to characterize ionic currents from intact lysosomes. Sci Signal. 2010;3(151):l. 3. doi: 10.1126/scisignal.3151pl3
- Schieder M, Rötzer K, Brüggemann A, et al. Characterization of two-pore channel 2 (TPCN2)-mediated Ca2+ currents in isolated lysosomes. J Biol Chem. 2010;285(28):21219–21222. doi: 10.1074/jbc.C110.143123
- Rojas CV, Wang JZ, Schwartz LS, et al. A Met-to-Val mutation in the skeletal muscle Na+ channel α-subunit in hyperkalaemic periodic paralysis. Nature. 1991;354:387–389. doi: 10.1038/354387a0
- OMIM - An online catalog of human genes and genetic disorders [internet]. Available from: https://www.omim.org/
- ClinVar [Internet]. Available from: https://www.ncbi.nlm.nih.gov/clinvar/
- Harraz OF, Delpire E. Recent insights into channelopathies. Physiol Rev. 2024;104(1):23–31. doi: 10.1152/physrev.00022.2023
- Carbone E, Mori Y. Ion channelopathies to bridge molecular lesions, channel function, and clinical therapies. Pflugers Arch - Eur J Physiol. 2020;472(7):733–738. doi: 10.1007/s00424-020-02424-y
- Prevarskaya N, Skryma R, Shuba Y. Ion channels in cancer: are cancer hallmarks oncochannelopathies? Physiol Rev. 2018;98(2):559–621. doi: 10.1152/physrev.00044.2016
- Mathews J, Kuchling F, Baez-Nieto D, et al. Ion channel drugs suppress cancer phenotype in NG108-15 and U87 cells: toward novel electroceuticals for glioblastoma. Cancers (Basel). 2022;14(6):1499. doi: 10.3390/cancers14061499
- Jiang S-H, Zhu L-L, Zhang M, et al. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GABA-independent manner. Gut. 2019;68(11):1994–2006. doi: 10.1136/gutjnl-2018-317479
- Cheng J, Novati G, Pan J, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science. 2023;381(6664):1284–1285. doi: 10.1126/science.adg7492
- Vanoye CG, Desai RR, Ji Z, et al. High-throughput evaluation of epilepsy-associated KCNQ2 variants reveals functional and pharmacological heterogeneity. J Clin Investig Insight. 2022;7:e156314. doi: 10.1172/jci.insight.156314
- Myers SJ, Yuan H, Perszyk RE, et al. Classification of missense variants in the N -methyl- d -aspartate receptor GRIN gene family as gain- or loss-of-function. Hum Mol Genet. 2023;32(19):2857–2871. doi: 10.1093/hmg/ddad104
- Shepard N, Baez-Nieto D, Iqbal S, et al. Differential functional consequences of GRIN2A mutations associated with schizophrenia and neurodevelopmental disorders. Sci Rep. 2024;14:2798. doi: 10.1038/s41598-024-53102-3
- Dutertre S, Lewis RJ. Use of venom peptides to probe ion channel structure and function. J Biol Chem. 2010;285(18):13315–13320. doi: 10.1074/jbc.R109.076596
- Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem. 2012;11:3029–3040. doi: 10.2174/0929867043363884
- Tarcha EJ, Olsen CM, Probst P, et al. Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: a randomized phase 1b trial. PLoS One. 2017;12(7):e0180762. doi: 10.1371/journal.pone.0180762
- Del Río-Sancho S, Cros C, Coutaz B, et al. Cutaneous iontophoresis of μ-conotoxin CnIIIC—A potent NaV1.4 antagonist with analgesic, anaesthetic and myorelaxant properties. Int J Pharm. 2017;518:59–65. doi: 10.1016/j.ijpharm.2016.12.054
- Jami S, Deuis JR, Klasfauseweh T, et al. Pain-causing stinging nettle toxins target TMEM233 to modulate NaV1.7 function. Nat Commun. 2023;14(1):2442. doi: 10.1038/s41467-023-37963-2
- Robinson SD, Deuis JR, Touchard A, et al. Ant venoms contain vertebrate-selective pain-causing sodium channel toxins. Nat Commun. 2023;14(1):2977. doi: 10.1038/s41467-023-38839-1
- Finol-Urdaneta RK, Zhorov BS, Baden DG, et al. Brevetoxin versus brevenal modulation of human NaV channels. Mar Drug. 2023;21(7):396. doi: 10.3390/md21070396
- Montnach J, Blömer LA, Lopez L, et al. In vivo spatiotemporal control of voltage-gated ion channels by using photoactivatable peptidic toxins. Nat Commun. 2022;13(1):417. doi: 10.1038/s41467-022-27974-w
- Hackney CM, Salcedo PF, Mueller E, et al. A previously unrecognized superfamily of macro-conotoxins includes an inhibitor of the sensory neuron calcium channel CaV2.3. PLoS Biol. 2023;21(8):e3002217. doi: 10.1371/journal.pbio.3002217
- Brun O, Zoukimian C, Oliveira-Mendes B, et al. Chemical synthesis of a functional fluorescent-tagged α-bungarotoxin. Toxins (Basel). 2022;14(2):79. doi: 10.3390/toxins14020079
- Murciano N, Rotordam MG, Becker N, et al. A high-throughput electrophysiology assay to study the response of PIEZO1 to mechanical stimulation. J Gen Physiol. 2023;155(12):e202213132. doi: 10.1085/jgp.202213132
- Li G, Huang D, Hong J, et al. Control of lysosomal TRPML1 channel activity and exosome release by acid ceramidase in mouse podocytes. Am J Physiol - Cell Physiol. 2019;317:C481–C491. 3 10.1152/ajpcell.00150.2019
- Brinkwirth N, Takasuna K, Doi M, et al. Reliable identification of cardiac liability in drug discovery using automated patch clamp: benchmarking best practices and calibration standards for improved proarrhythmic assessment. J Pharmacol Toxicol Methods. 2020;105:106884. doi: 10.1016/j.vascn.2020.106884
- Rotordam MG, Obergrussberger A, Brinkwirth N, et al. Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: best practices for NaV1.5 peak current in a high throughput screening environment. J Pharmacol Toxicol Methods. 2021;112:107125. doi: 10.1016/j.vascn.2021.107125
- Windley MJ, Farr J, TeBay C, et al. High throughput measurement of hERG drug block kinetics using the CiPA dynamic protocol. J Pharmacol Toxicol Methods. 2022;117:107192. doi: 10.1016/j.vascn.2022.107192
- Montnach J, Lorenzini M, Lesage A, et al. Computer modeling of whole-cell voltage-clamp analyses to delineate guidelines for good practice of manual and automated patch-clamp. Sci Rep. 2021;11(1):3282. doi: 10.1038/s41598-021-82077-8
- Brown GE, Han YD, Michell AR, et al. Engineered cocultures of iPSC-derived atrial cardiomyocytes and atrial fibroblasts for modeling atrial fibrillation. Sci Adv. 2024;10(3):eadg1222. doi: 10.1126/sciadv.adg1222
- Bloothooft M, Verbruggen B, Seibertz F, et al. Recording ten-fold larger IKr conductances with automated patch clamping using equimolar Cs+ solutions. Front Physiol. 2024;15:1298340. doi: 10.3389/fphys.2024.1298340
- Berecki G, Howell KB, Deerasooriya YH, et al. Dynamic action potential clamp predicts functional separation in mild familial and severe de novo forms of SCN2A epilepsy. Proc Natl Acad Sci U S A. 2018;115(24):E5516–E5525. doi: 10.1073/pnas.1800077115
- Govorunova EG, Sineshchekov OA, Brown LS, et al. Biophysical characterization of light-gated ion channels using planar automated patch clamp. Front Mol Neurosci. 2022;15:976910. doi: 10.3389/fnmol.2022.976910